Review





Similar Products

93
Miltenyi Biotec antibodies against cd138
Antibodies Against Cd138, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against cd138/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
antibodies against cd138 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

94
Boster Bio cd138
Cd138, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138/product/Boster Bio
Average 94 stars, based on 1 article reviews
cd138 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cd138 microbeads
Anti Cd138 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd138 microbeads/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cd138 microbeads - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cd138 magnetic activated cell separation microbeads
Anti Cd138 Magnetic Activated Cell Separation Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd138 magnetic activated cell separation microbeads/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cd138 magnetic activated cell separation microbeads - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Proteintech cd86
Cd86, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd86/product/Proteintech
Average 94 stars, based on 1 article reviews
cd86 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Proteintech sdc1
MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length <t>SDC1</t> and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.
Sdc1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sdc1/product/Proteintech
Average 94 stars, based on 1 article reviews
sdc1 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Proteintech anti cd138
MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length <t>SDC1</t> and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.
Anti Cd138, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd138/product/Proteintech
Average 94 stars, based on 1 article reviews
anti cd138 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
Proteintech mouse
MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length <t>SDC1</t> and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.
Mouse, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse/product/Proteintech
Average 94 stars, based on 1 article reviews
mouse - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Miltenyi Biotec cd138 antibody, anti-mouse, reafinity
MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length <t>SDC1</t> and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.
Cd138 Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd138 antibody, anti-mouse, reafinity/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
cd138 antibody, anti-mouse, reafinity - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length SDC1 and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.

Journal: The Journal of Biological Chemistry

Article Title: Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles

doi: 10.1016/j.jbc.2026.111182

Figure Lengend Snippet: MG132 inhibits the degradation of SDC4-CTF. A and B , Western blot of HCT116 cells treated with 0.5, 1, 2.5, or 5 μM MG132 for 12 h, or with 2.5 μM MG132 for 0 to 12 h. C , Western blot of full-length SDC1 and SDC4 in HCT116 cells treated with MG132 (0.5–5 μM, 12 h). D and E , immunofluorescence detection and quantification of HCT116 cells transfected with SDC1-GFP or SDC4-GFP, with/without 5 μM MG132 (4 h; n = 6). F , Western blot of multiple colorectal cancer cell lines treated with 10 μM MG132 (12 h). G , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 0.1, 0.5, or 1 μM proteasome inhibitors (Carfilzomib, Ixazomib, Bortezomib) for 24 h. H , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with PD150606 (2, 5, 10 μM) for 12 h. I , quantification of DQ-BSA fluorescence with MG132 or Earle’s balanced salt solution (EBSS) treatment (n = 4). J , quantification of lysosomal activity using LysoTracker with MG132 or EBSS treatment (n = 4). K , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with siRNA knockdown of proteasome subunits PSMD14, PSMD2, USP14, PSMB5, PSMA6. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, syndecan4; CTF, C-terminal transmembrane (TM) fragment; EBSS, Earle’s balanced salt solution.

Article Snippet: Antibodies against LC3 (14600-1-AP), LAMP2 (66301-1-Ig), p62 (18420-1-AP), Syntenin (22399-1-AP), CD63 (25682-1-AP), TSG101 (28283-1-AP), CD9 (20597-1-AP), α-tubulin (11,224–1-AP), PSMA6 (67695-1-Ig), PSMED2 (14748-1-AP), USP14 (67746-1-Ig), and SDC1 (10593-1-AP) for SDC1-FL detection were obtained from Proteintech. β-catenin (ab16051) and PSMD14 (ab109123) antibodies were obtained from Abcam.

Techniques: Western Blot, Immunofluorescence, Transfection, Fluorescence, Activity Assay, Knockdown, Two Tailed Test

SDC4-CTF is further cleaved by γ-secretase to release the cytoplasmic fragment. A , confocal microscopy of HCT116 cells transfected with SDC4-GFP or SDC4-CTF-GFP. B , schematic of SDC4-GFP deletion mutants, SNP for Signal peptide, ED for ectodomain, TM for TM motif, C1 and C2 for the constant regions, and V for variable region. C , Western blot of HCT116 cells transfected with SDC1-GFP, SDC4-GFP, or SDC4-CTF-GFP, with/without 5 μM MG132 (4 h). D , sequence alignment of Syndecan family TM C-terminal fragments. The alignment was performed using Clustal W, and analysis was done with ESPript 3.0. E , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with presenilin-1 knockdown (siRNA, 72 h). F , Western blot of HCT116 and SW480 cells treated with 10 μM DAPT, 10 μM MG132, or 2.5 μM GM6001 (12 h). G , schematic of SDC4-CTF degradation via lysosome or proteasome pathways. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, Syndecan4; CTF, C-terminal transmembrane fragment.

Journal: The Journal of Biological Chemistry

Article Title: Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles

doi: 10.1016/j.jbc.2026.111182

Figure Lengend Snippet: SDC4-CTF is further cleaved by γ-secretase to release the cytoplasmic fragment. A , confocal microscopy of HCT116 cells transfected with SDC4-GFP or SDC4-CTF-GFP. B , schematic of SDC4-GFP deletion mutants, SNP for Signal peptide, ED for ectodomain, TM for TM motif, C1 and C2 for the constant regions, and V for variable region. C , Western blot of HCT116 cells transfected with SDC1-GFP, SDC4-GFP, or SDC4-CTF-GFP, with/without 5 μM MG132 (4 h). D , sequence alignment of Syndecan family TM C-terminal fragments. The alignment was performed using Clustal W, and analysis was done with ESPript 3.0. E , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells with presenilin-1 knockdown (siRNA, 72 h). F , Western blot of HCT116 and SW480 cells treated with 10 μM DAPT, 10 μM MG132, or 2.5 μM GM6001 (12 h). G , schematic of SDC4-CTF degradation via lysosome or proteasome pathways. Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ∗∗∗∗ p < 0.0001). SDC4, Syndecan4; CTF, C-terminal transmembrane fragment.

Article Snippet: Antibodies against LC3 (14600-1-AP), LAMP2 (66301-1-Ig), p62 (18420-1-AP), Syntenin (22399-1-AP), CD63 (25682-1-AP), TSG101 (28283-1-AP), CD9 (20597-1-AP), α-tubulin (11,224–1-AP), PSMA6 (67695-1-Ig), PSMED2 (14748-1-AP), USP14 (67746-1-Ig), and SDC1 (10593-1-AP) for SDC1-FL detection were obtained from Proteintech. β-catenin (ab16051) and PSMD14 (ab109123) antibodies were obtained from Abcam.

Techniques: Confocal Microscopy, Transfection, Western Blot, Sequencing, Knockdown, Two Tailed Test

Syntenin stabilizes SDC4-CTF against endocytic-lysosomal degradation. A , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 25 μM LY294002, 250 nM Rapamycin, or 250 nM Bafilomycin A1. B , Western blot of HCT116 cells starved in EBSS for indicated durations. C and D , Western blot and quantification of SDC1-CTF and SDC4-CTF in HCT116 cells overexpressing Flag-tagged Syntenin (n = 3). E , schematic and sequences of SDC4 WT and SDC4 ΔC2 , with confocal images of indicated plasmids in 293T cells. F , quantification of fluorescence co-localization from ( E ) (n = 6). G and H , Western blot and quantification of SDC4-CTF and Syntenin in 293T cells co-transfected with SDC4 and GFP-tagged Syntenin (n = 3). I , Western blot of SDC1-CTF, SDC4-CTF, and Syntenin in multiple cancer cell lines. J , correlation analysis between SDC4-CTF and Syntenin expression from ( I ). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ns). SDC4, Syndecan4; CTF, C-terminal transmembrane fragment; EBSS, Earle’s balanced salt solution.

Journal: The Journal of Biological Chemistry

Article Title: Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles

doi: 10.1016/j.jbc.2026.111182

Figure Lengend Snippet: Syntenin stabilizes SDC4-CTF against endocytic-lysosomal degradation. A , Western blot of SDC1-CTF and SDC4-CTF in HCT116 cells treated with 25 μM LY294002, 250 nM Rapamycin, or 250 nM Bafilomycin A1. B , Western blot of HCT116 cells starved in EBSS for indicated durations. C and D , Western blot and quantification of SDC1-CTF and SDC4-CTF in HCT116 cells overexpressing Flag-tagged Syntenin (n = 3). E , schematic and sequences of SDC4 WT and SDC4 ΔC2 , with confocal images of indicated plasmids in 293T cells. F , quantification of fluorescence co-localization from ( E ) (n = 6). G and H , Western blot and quantification of SDC4-CTF and Syntenin in 293T cells co-transfected with SDC4 and GFP-tagged Syntenin (n = 3). I , Western blot of SDC1-CTF, SDC4-CTF, and Syntenin in multiple cancer cell lines. J , correlation analysis between SDC4-CTF and Syntenin expression from ( I ). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ns). SDC4, Syndecan4; CTF, C-terminal transmembrane fragment; EBSS, Earle’s balanced salt solution.

Article Snippet: Antibodies against LC3 (14600-1-AP), LAMP2 (66301-1-Ig), p62 (18420-1-AP), Syntenin (22399-1-AP), CD63 (25682-1-AP), TSG101 (28283-1-AP), CD9 (20597-1-AP), α-tubulin (11,224–1-AP), PSMA6 (67695-1-Ig), PSMED2 (14748-1-AP), USP14 (67746-1-Ig), and SDC1 (10593-1-AP) for SDC1-FL detection were obtained from Proteintech. β-catenin (ab16051) and PSMD14 (ab109123) antibodies were obtained from Abcam.

Techniques: Western Blot, Fluorescence, Transfection, Expressing, Two Tailed Test

AGO binds to SDC4 and disrupts SDC4-Syntenin interaction. A , chemical structure of AGO. B , microscale thermophoresis (MST) assays of AGO with GFP-SDC4 or GFP control in 293T lysate (n = 3). C , MST assays of AGO with recombinant glutathione S-transferase (GST)-SDC4 (n = 3). D and E , MST assays of AGO with GFP-tagged SDC4 or SDC1 and their TM deletion mutants (n = 3 each). F and G , Western blot and quantification of AGO drug affinity responsive target stability experiments (n = 3). H and I , immunoprecipitation (IP) and quantification of SDC4 binding to Syntenin in SW480 cells treated with 20 μM AGO (24 h; n = 3). J , IP of Flag-Syntenin and GFP-SDC4 in 293T cells treated with 20 μM AGO (24 h). K , GST pull-down of Syntenin from 293T lysate with/without 20 μM AGO, using GST or GST-SDC4. L and M , poximity ligation assays and quantification of SDC4-Syntenin interaction in SW480 cells treated with 20 μM AGO (24 h; n = 8). O and P , confocal images and quantification of SDC4/GFP-Syntenin co-localization in 293T cells treated with 20 μM AGO (24 h; n = 8). Q , IP of SDC4 and detection of GFP-Syntenin/endogenous Syntenin in 293T cells treated with 20 μM AGO (24 h). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ns). AGO, Andrographolide; GST, glutathione S-transferase; SDC4, Syndecan4; MST, microscale thermophoresis; TM, transmembrane; IP, immunoprecipitation.

Journal: The Journal of Biological Chemistry

Article Title: Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles

doi: 10.1016/j.jbc.2026.111182

Figure Lengend Snippet: AGO binds to SDC4 and disrupts SDC4-Syntenin interaction. A , chemical structure of AGO. B , microscale thermophoresis (MST) assays of AGO with GFP-SDC4 or GFP control in 293T lysate (n = 3). C , MST assays of AGO with recombinant glutathione S-transferase (GST)-SDC4 (n = 3). D and E , MST assays of AGO with GFP-tagged SDC4 or SDC1 and their TM deletion mutants (n = 3 each). F and G , Western blot and quantification of AGO drug affinity responsive target stability experiments (n = 3). H and I , immunoprecipitation (IP) and quantification of SDC4 binding to Syntenin in SW480 cells treated with 20 μM AGO (24 h; n = 3). J , IP of Flag-Syntenin and GFP-SDC4 in 293T cells treated with 20 μM AGO (24 h). K , GST pull-down of Syntenin from 293T lysate with/without 20 μM AGO, using GST or GST-SDC4. L and M , poximity ligation assays and quantification of SDC4-Syntenin interaction in SW480 cells treated with 20 μM AGO (24 h; n = 8). O and P , confocal images and quantification of SDC4/GFP-Syntenin co-localization in 293T cells treated with 20 μM AGO (24 h; n = 8). Q , IP of SDC4 and detection of GFP-Syntenin/endogenous Syntenin in 293T cells treated with 20 μM AGO (24 h). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗∗ p < 0.001, ∗∗∗ p < 0.0005, ns). AGO, Andrographolide; GST, glutathione S-transferase; SDC4, Syndecan4; MST, microscale thermophoresis; TM, transmembrane; IP, immunoprecipitation.

Article Snippet: Antibodies against LC3 (14600-1-AP), LAMP2 (66301-1-Ig), p62 (18420-1-AP), Syntenin (22399-1-AP), CD63 (25682-1-AP), TSG101 (28283-1-AP), CD9 (20597-1-AP), α-tubulin (11,224–1-AP), PSMA6 (67695-1-Ig), PSMED2 (14748-1-AP), USP14 (67746-1-Ig), and SDC1 (10593-1-AP) for SDC1-FL detection were obtained from Proteintech. β-catenin (ab16051) and PSMD14 (ab109123) antibodies were obtained from Abcam.

Techniques: Microscale Thermophoresis, Control, Recombinant, Western Blot, Immunoprecipitation, Binding Assay, Ligation, Two Tailed Test

AGO promotes lysosomal degradation of SDC4-CTF. A , Western blot of SDC1/4 CTF and full-length in SW480 cells treated with AGO (indicated doses, 24 h; n = 3). B , Western blot in SW480 cells treated with 20 μM AGO for 0 to 24 h. C and D , immunofluorescence detection and quantification of SDC4 in SW480 cells treated with 20 μM AGO (24 h; n = 6). E , surface SDC4 measured by FACS using FITC-anti-SDC4. F , Western blot of SDC1/4 CTF and full-length in HCT116 cells treated with AGO (indicated doses, 24 h). G , Western blot of SDC4-CTF in multiple colorectal cancer cells treated with 20 μM AGO (24 h). H , Western blot of SDC1-CTF and SDC4-CTF in SW480 cells treated with cycloheximide (50 μg/ml) along with/without 20 μM AGO for indicated times. I , RT-qPCR of indicated genes in SW480 cells treated with 20 μM AGO (24 h; n = 4). J , Western blot of SDC1-CTF and SDC4-CTF in SW480 cells treated with 20 μM AGO, 2.5 μM GM6001, 10 μM TMI-1, or combinations (24 h). K , Western blot in SW480 cells treated with 20 μM AGO, 5 μM BAY11 to 7082, 10 nM PMA, 1 μg/ml LPS, or 20 μg/ml TNFα (24 h). L and M , live-cell imaging and analysis of SDC4-GFP intensity in 293T cells co-expressing DsRed-Rab5A and SDC4-GFP, with 20 μM AGO treatment (n = 4). O , Western blot of lysosome markers and SDC1/4-CTF in SW480 cells treated with 20 μM AGO, 250 nM BAF1, or combination (24 h). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗ p < 0.05, ∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns). AGO, andrographolide; SDC4, Syndecan4; CTF, C-terminal transmembrane fragment; FACS, fluorescence-activated cell sorting; BAF1, Bafilomycin A1.

Journal: The Journal of Biological Chemistry

Article Title: Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles

doi: 10.1016/j.jbc.2026.111182

Figure Lengend Snippet: AGO promotes lysosomal degradation of SDC4-CTF. A , Western blot of SDC1/4 CTF and full-length in SW480 cells treated with AGO (indicated doses, 24 h; n = 3). B , Western blot in SW480 cells treated with 20 μM AGO for 0 to 24 h. C and D , immunofluorescence detection and quantification of SDC4 in SW480 cells treated with 20 μM AGO (24 h; n = 6). E , surface SDC4 measured by FACS using FITC-anti-SDC4. F , Western blot of SDC1/4 CTF and full-length in HCT116 cells treated with AGO (indicated doses, 24 h). G , Western blot of SDC4-CTF in multiple colorectal cancer cells treated with 20 μM AGO (24 h). H , Western blot of SDC1-CTF and SDC4-CTF in SW480 cells treated with cycloheximide (50 μg/ml) along with/without 20 μM AGO for indicated times. I , RT-qPCR of indicated genes in SW480 cells treated with 20 μM AGO (24 h; n = 4). J , Western blot of SDC1-CTF and SDC4-CTF in SW480 cells treated with 20 μM AGO, 2.5 μM GM6001, 10 μM TMI-1, or combinations (24 h). K , Western blot in SW480 cells treated with 20 μM AGO, 5 μM BAY11 to 7082, 10 nM PMA, 1 μg/ml LPS, or 20 μg/ml TNFα (24 h). L and M , live-cell imaging and analysis of SDC4-GFP intensity in 293T cells co-expressing DsRed-Rab5A and SDC4-GFP, with 20 μM AGO treatment (n = 4). O , Western blot of lysosome markers and SDC1/4-CTF in SW480 cells treated with 20 μM AGO, 250 nM BAF1, or combination (24 h). Data: mean ± SD (≥3 experiments). Statistics: unpaired two-tailed t test (∗ p < 0.05, ∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns). AGO, andrographolide; SDC4, Syndecan4; CTF, C-terminal transmembrane fragment; FACS, fluorescence-activated cell sorting; BAF1, Bafilomycin A1.

Article Snippet: Antibodies against LC3 (14600-1-AP), LAMP2 (66301-1-Ig), p62 (18420-1-AP), Syntenin (22399-1-AP), CD63 (25682-1-AP), TSG101 (28283-1-AP), CD9 (20597-1-AP), α-tubulin (11,224–1-AP), PSMA6 (67695-1-Ig), PSMED2 (14748-1-AP), USP14 (67746-1-Ig), and SDC1 (10593-1-AP) for SDC1-FL detection were obtained from Proteintech. β-catenin (ab16051) and PSMD14 (ab109123) antibodies were obtained from Abcam.

Techniques: Western Blot, Immunofluorescence, Quantitative RT-PCR, Live Cell Imaging, Expressing, Two Tailed Test, Fluorescence, FACS